公开(公告)号：US09579376B2

公开(公告)日：2017-02-28

申请号：US14727666

申请日：2015-06-01

申请人： University of Washington ,  Fred Hutchinson Cancer Research Center

发明人： Lawrence Corey ,  Kerry J. Laing ,  Anna Wald ,  David M. Koelle

IPC分类号： A61K39/245 ,  C12N7/00 ,  C07K14/005 ,  A61K39/00 ,  A61K9/00

CPC分类号： A61K39/245 ,  A61K9/0019 ,  A61K39/00 ,  A61K2039/5158 ,  C07K14/005 ,  C12N7/00 ,  C12N2710/16622 ,  C12N2710/16634

摘要： The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection, including epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.

摘要翻译： 本发明提供了可用于预防和治疗HSV感染的HSV抗原，包括确认为来自疱疹病变的T细胞识别的表位。 对本发明的抗原具有特异性的T细胞已经证明了对负载有病毒编码的肽表位的细胞的细胞毒性活性，并且在许多情况下，针对感染HSV的细胞。 鉴定负责T细胞特异性的免疫原性抗原提供了改进的抗病毒治疗和预防策略。 含有编码本发明抗原的抗原或多核苷酸的组合物提供有效靶向的疫苗，用于预防和治疗HSV感染。

公开(公告)号：US20150335734A1

公开(公告)日：2015-11-26

申请号：US14727666

申请日：2015-06-01

申请人： University of Washington ,  Fred Hutchinson Cancer Research Center

发明人： Lawrence Corey ,  Kerry J. Laing ,  Anna Wald ,  David M. Koelle

IPC分类号： A61K39/245 ,  C12N7/00

CPC分类号： A61K39/245 ,  A61K9/0019 ,  A61K39/00 ,  A61K2039/5158 ,  C07K14/005 ,  C12N7/00 ,  C12N2710/16622 ,  C12N2710/16634

摘要： The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection, including epitopes confirmed to be recognized by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.

摘要翻译： 本发明提供了可用于预防和治疗HSV感染的HSV抗原，包括确认为来自疱疹病变的T细胞识别的表位。 对本发明的抗原具有特异性的T细胞已经证明了对负载有病毒编码的肽表位的细胞的细胞毒性活性，并且在许多情况下，针对感染HSV的细胞。 鉴定负责T细胞特异性的免疫原性抗原提供了改进的抗病毒治疗和预防策略。 含有编码本发明抗原的抗原或多核苷酸的组合物提供有效靶向的疫苗，用于预防和治疗HSV感染。

公开(公告)号：US20200164060A1

公开(公告)日：2020-05-28

申请号：US16632853

申请日：2018-07-20

申请人： Fred Hutchinson Cancer Research Center ,  University of Washington

发明人： David Koelle ,  Anna Wald ,  Christine Johnston ,  Christine Posavad ,  Larry Corey

IPC分类号： A61K39/245 ,  C12N7/00 ,  C07K14/005 ,  C07K14/705 ,  C07K14/73

摘要： Herpes Simplex Virus type 2 (HSV-2) epitopes bound by CD8 or CD4 tissue resident memory cells at a healed site of HSV-2 infection are disclosed. The HSV-2 epitopes can be used as immunogenic compositions to elicit protective immune responses against HSV-2.